- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Generalised myasthenia gravis (gMG)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Rozanolixizumab – March 2025
Rozanolixizumab; Solution for subcutaneous infusion 280 mg in 2 mL (140 mg per mL); Rystiggo®
Last updated
12 February 2026